Explore. Learn. Join the conversation.

Working Group on New TB Drugs

Stop TB Partnership

TB R&D Weekly Update: Podcast Interview with Dr. Yossef Av-Gay

avgayweb111380

This week we interview Dr. Yossef Av-Gay and discuss his recently published paper, his contribution to TB drug discovery and the focus of his research. Dr. Av-Gay, a professor in the Division of Infectious Diseases at the University of British Columbia, recently published a paper in PNAS that provides evidence to that points to a specific protein that allows Mtb to bypass the body’s defenses. Additional TB R&D news links are included.

TB R&D Weekly Update: Novel Compounds Screened for DS and MDR-TB

aaac cover_home

This week’s featured article from Bill Jacob’s lab looks at novel InhA (target of isoniazid (INH), a first-line TB drug) inhibitors and their ability to kill M. tuberculosis (M.tb) that is drug-sensitive, resistant and in dormant stage. Two compounds were identified that had significant bactericidal activity against M.tb: CD 39 and CD117. Additional links to TB R&D News are included.

TB R&D Weekly Update: P27-P55 Operon of Mtb and Drug Resistance

bmclogo

his week, we present an article from researchers from the Instituto de Biotecnologia and TB Control Program in Buenos Aires, Argentina. The article focuses on the P27-P55 operon which has been shown in mice to be essential for M. tuberculosis (M. tb) to survive in the host. Additional links to TB R&D news are included.

21 Jun 2011
by Christopher Cooper

Posted in Early Drug Development, TB Drug Development

TB R&D Weekly Update: Potential Use of Polyether Ionophores Against TB

polyether ionophores

During this week’s TB R&D Weekly Update, we explore the potential of polyether ionophores as anti-tuberculosis agents in an article published in 2009 by Kevin, et al. Links to additional TB R&D News are included.

TB R&D Weekly Update: Efflux and Rifampicin Resistance

AJResp and Critical Care cover

This week we look again at the role of efflux pumps in resistance to anti-tuberculosis drugs. Louw, et al., sought to “demonstrate that the level of rifampicin resistance is defined by efflux, which regulates the intracellular concentration of rifampicin.” This is a shift from the current thinking in the field that rifampicin resistance is solely the result of mutations in the rpoB gene. The article entitled “Rifampicin Reduces Susceptibility to Ofloxacin in Rifampicin Resistant Mycobacterium tuberculosis through Efflux” was published ahead of print in the American Journal of Respiratory and Critical Care Medicine. Additional links to TB R&D News is included.

TB R&D Weekly Update: Podcast interview on TB Drug Tolerance and Efflux Pumps

ramakrishnan

The WGND had the opportunity to interview three researchers (Lalita Ramakrishnan, Paul Edelstein, and Christine Cosma) involved in the groundbreaking research on the role of efflux pumps in contributing to drug tolerance during TB treatment which was published in the April 1 issue of Cell. Additional links to TB R&D News are included.

TB R&D Weekly Update: Drugs Targeting MMP-1 May Reduce Lung Pathology Caused by TB

jci2011crop

In this week’s article which was published online ahead of print, Elkington, et al., presents significant data to support the premise that M. tuberculosis infection drives proteolytic destruction of the lung matrix contributing to lung damage caused by TB and to the morbidity and mortality of TB. Additional links to TB R&D News are included.

TB R&D Weekly Update: Marine Drug Discovery Symposium at the NYAS

NYAS

This week in TB R&D, we are highlighting a symposium hosted by The New York Academy of Sciences entitled “New Frontiers in Marine Drug Discovery” on May 20, 2011. This 1-day symposium will overview the current state of the art in Marine Biomedicine and its role in the context of the drug discovery process. Additional TB R&D news links are included.

First Chinese Product Development Partnership for TB, Malaria and HIV/AIDS Announced

partner

Today on World TB Day, the International Scientific Exchange Foundation of China (ISEFC), announced the signing of a Memorandum of Understanding with the Global Alliance for TB Drug Development (TB Alliance) to establish the Global Health R&D Center of China (GHRC). This innovative center will focus on the development of treatments for the world’s leading infectious disease killers—tuberculosis, malaria, and HIV/AIDS.

10 Mar 2011

BIO Ventures for Global Health Launches New Online Tool

Picture1

This week BIO Ventures for Global Health launched a new online tool called the “Global Health Primer” which aims to be a clearinghouse of information geared to the biotech industry to encourage investments in neglected disease product development.